UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Location
9 Ha'ta'asiya St, Ra'anana, Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 494 % -34.5%
Quick Ratio 18.2 % -19.1%
Debt-to-equity -451 % +77.9%
Return On Equity 249 % -73.2%
Return On Assets -71 % -48.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.8M shares +10.9%
Common Stock, Shares, Outstanding 46.8M shares +10.9%
Entity Public Float 675M USD +255%
Common Stock, Value, Issued 128K USD +11.3%
Weighted Average Number of Shares Outstanding, Basic 48.1M shares +2.73%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 96.5M USD +8%
Cost of Revenue 11.6M USD +33.7%
Research and Development Expense 67.7M USD +26.4%
Operating Income (Loss) -133M USD -59.3%
Nonoperating Income (Expense) -727K USD -213%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -162M USD -45.2%
Income Tax Expense (Benefit) 3M USD -25.6%
Net Income (Loss) Attributable to Parent -165M USD -42.7%
Earnings Per Share, Basic -3 USD/shares -18.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 90M USD -27.9%
Cash, Cash Equivalents, and Short-term Investments 127M USD -49.9%
Accounts Receivable, after Allowance for Credit Loss, Current 19.7M USD -13.6%
Inventory, Net 8.34M USD +9.84%
Assets, Current 169M USD -42.9%
Property, Plant and Equipment, Net 695K USD +14.3%
Operating Lease, Right-of-Use Asset 3.1M USD +194%
Other Assets, Noncurrent 6.76M USD +1727%
Assets 185M USD -38.7%
Accounts Payable, Current 10.3M USD +85%
Employee-related Liabilities, Current 11.1M USD +23.1%
Liabilities, Current 42.2M USD +28.8%
Operating Lease, Liability, Noncurrent 2.67M USD +1161%
Liabilities 300M USD +8.69%
Accumulated Other Comprehensive Income (Loss), Net of Tax 23K USD -90.3%
Retained Earnings (Accumulated Deficit) -933M USD -21.4%
Stockholders' Equity Attributable to Parent -115M USD -552%
Liabilities and Equity 185M USD -38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42M USD -32.4%
Net Cash Provided by (Used in) Financing Activities 54.7M USD +8046%
Net Cash Provided by (Used in) Investing Activities -26M USD -292%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 46.8M shares +10.9%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -68M USD -286%
Deferred Tax Assets, Valuation Allowance 169M USD +17.4%
Deferred Tax Assets, Gross 169M USD +17.7%
Operating Lease, Liability 3.1M USD +199%
Payments to Acquire Property, Plant, and Equipment 44K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -165M USD -43.3%
Lessee, Operating Lease, Liability, to be Paid 4.11M USD +275%
Property, Plant and Equipment, Gross 5.21M USD +8.03%
Operating Lease, Liability, Current 429K USD -48%
Lessee, Operating Lease, Liability, to be Paid, Year Two 887K USD +1429%
Lessee, Operating Lease, Liability, to be Paid, Year One 747K USD -8.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +19.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.01M USD +1580%
Lessee, Operating Lease, Liability, to be Paid, Year Three 821K USD
Deferred Tax Assets, Operating Loss Carryforwards 123M USD +18.7%
Unrecognized Tax Benefits 3.8M USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 603K USD
Operating Lease, Payments 220K USD -20.6%
Depreciation, Depletion and Amortization 278K USD -45.3%
Deferred Tax Assets, Net of Valuation Allowance 769K USD +140%
Share-based Payment Arrangement, Expense 12.1M USD -2.3%